Thermo Fisher Scientific Inc. research snapshot
TMO AI stock analysis currently reads Thermo Fisher Scientific as a high-quality life sciences tools, diagnostics, analytical instruments, and biopharma services platform that is recovering from a slower post-pandemic demand cycle. At the July 8, 2026 data cutoff, TMO traded near $510.00 with a verified market cap near $189.53 billion, a trailing PE near 28.04x, and free cash flow yield near 3.56%. The TMO AI stock forecast is constructive on business quality and Q1 2026 execution, but scenario-based on price because organic growth, China demand, Clario integration, leverage, and multiple compression still matter.
Current price
$510.00
Market cap
$189.53 billion verified market cap
AI score
70 / 100
Rating
High-quality life sciences platform with moderate margin of safety at the current valuation
Trend status
Short-term rebound above the 50-day average, still below the 200-day average and January 2026 high
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Thermo Fisher sells tools, consumables, instruments, diagnostics, lab services, CDMO services, and CRO services that sit inside recurring scientific, pharma, biotech, academic, government, and clinical workflows. | High |
| Moat | The moat comes from scale, breadth, trusted brands, workflow integration, regulated customer qualification, recurring consumables, procurement convenience, and the PPI operating system. | High |
| Management | Marc Casper has been CEO since 2009 and chairman since 2020, giving the company unusually long strategic continuity, but succession and acquisition discipline remain key monitoring items. | High |
| Financial trend | FY2025 revenue grew 4% to $44.56 billion, adjusted EPS grew 5% to $22.87, and Q1 2026 revenue grew 6% to $11.01 billion with adjusted EPS of $5.44. | High |
| Valuation | At $510.00, TMO screens near 28.04x TTM EPS, 28.08x free cash flow per share, 3.65x book value, and 4.19x sales. | High |
| Technical trend | The stock has rebounded above its 50-day moving average near $474.47, but it remains below the 200-day average near $526.87 and the 52-week high near $643.99. | Medium |
| Risk level | Risks include biotech funding cycles, China and tariff exposure, government and academic budgets, Clario integration, debt load, goodwill impairment risk, and valuation multiple compression. | Medium-high |
| AI confidence | Descriptive confidence is high because company filings and market data align. Forecast confidence is lower because end-market recovery and valuation multiples are unstable. | High data confidence |
| Investment certainty | TMO is a quality compounder candidate, but the current price provides only moderate margin of safety unless organic growth and EPS compounding accelerate. | Medium |
TMO AI stock forecast
The TMO AI stock forecast uses the $510.00 price reference, TTM EPS near $18.19, and a three-year scenario model. The audited model produced a bearish area near $348, a base area near $550, and a bullish area near $767 before any future dividends or buybacks. The range is wide because Thermo Fisher combines durable scale advantages with cyclical life sciences demand and acquisition-related leverage.
$735 to $790
More likely if organic revenue growth moves toward the company long-term target, biotech funding improves, China stabilizes, Clario adds earnings without balance-sheet strain, and the market rewards TMO with a premium earnings multiple.
$525 to $575
More likely if revenue grows in the mid-single-digit range, adjusted EPS grows high single digits, free cash flow conversion improves, and the market values TMO near a mid-20s earnings multiple.
$330 to $365
More likely if pharma and biotech spending weakens, China and tariff pressure persist, Clario integration disappoints, leverage slows buybacks, or investors re-rate life sciences tools toward a high-teens PE.
TMO AI technical analysis
TMO AI technical analysis is mixed as of the July 8, 2026 cutoff. StockAnalysis showed an intraday reference near $510.00, a 50-day moving average near $474.47, a 200-day moving average near $526.87, RSI near 62.80, and 20-day average volume near 2.19 million shares. MarketWatch showed a 52-week range of $403.36 to $643.99, so the rebound is real but not yet a clean long-term trend reclaim.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $510.00 | Market-data reference used for valuation and market-cap checks at the July 8, 2026 data cutoff. |
| Immediate support | $470 to $480 | This zone brackets the 50-day moving average reference near $474.47 and the recent rebound base. |
| Deeper support | $403 to $425 | This area brackets the lower part of the 52-week range and would signal that the recovery thesis is being retested. |
| Near resistance | $525 to $530 | This zone overlaps the 200-day moving average reference near $526.87 and is the first major trend test. |
| Higher resistance | $596 to $644 | The average analyst target near $596.26 and the 52-week high near $643.99 define the next upside reference band. |
| Moving averages | 50-day near $474.47, 200-day near $526.87 | Price is above the 50-day average but below the 200-day average, which makes the setup a rebound rather than a confirmed long-term breakout. |
| Momentum | RSI near 62.80 | Momentum is positive but not yet extreme, so confirmation depends on whether price can hold above the 50-day area and reclaim the 200-day area. |
| Volume | 20-day average near 2.19 million shares | Volume confirmation matters around the July 23, 2026 earnings date because guidance can reset the technical range quickly. |
| Volatility | Watch Q2 earnings, guidance, Clario, China, and tariff language | Earnings commentary can change expectations for organic growth, margin recovery, leverage, and acquisition contribution. |
| Invalidation | Close below $470, then below $403 | A close below the 50-day area weakens the rebound setup. A break below the 52-week low would invalidate the current recovery framework. |
TMO AI trading strategy
The TMO AI trading strategy below is a rules-based research framework, not personalized advice. It connects price behavior with life sciences demand, organic growth, Clario integration, free cash flow, leverage, China exposure, and valuation discipline.
Watch for TMO to hold the $470 to $480 support area and then reclaim the $525 to $530 resistance band while Q2 results confirm organic growth, adjusted EPS progress, free cash flow recovery, and stable guidance.
A failed reclaim followed by a close below $470 should reduce trend confidence, especially if management commentary points to weaker biotech funding, China softness, tariffs, or Clario integration costs.
If TMO pulls back toward the $403 to $425 area without damage to long-term demand, cash generation, or balance-sheet repair, compare the lower price with Thermo Fisher quality and the base-case valuation range.
Do not treat a lower price as automatically attractive if EPS revisions fall, debt reduction slows, goodwill risk rises, or organic growth remains stuck near low single digits.
Track Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services, order trends, China demand, biopharma funding, Clario integration, free cash flow conversion, and leverage.
Position sizing should reflect that TMO is a quality healthcare infrastructure company with cyclical and debt-sensitive exposures, not a guaranteed defensive growth trade.
Investment research summary
Customers pay Thermo Fisher because scientific research, pharma development, diagnostics, laboratory operations, and biopharma services require reliable tools, consumables, instruments, software, and outsourced capabilities that reduce workflow risk.
The moat is strongest in scale, brand trust, procurement breadth, installed workflows, regulated qualification, recurring consumables, service networks, and acquisition integration. It is weaker where capital equipment demand turns cyclical.
The thesis fails if biopharma and academic budgets weaken, China demand disappoints, tariffs pressure margins, Clario integration consumes capital, debt limits buybacks, or investors stop paying a premium multiple for life sciences tools.
Marc Casper has led the company since 2009 and has overseen major portfolio expansion through Life Technologies, Patheon, PPD, Olink, and Clario. The key test is whether the next phase balances acquisitions, debt reduction, buybacks, and organic innovation.
Thermo Fisher benefits from long-term growth in biologics, diagnostics, precision medicine, analytical testing, pharma outsourcing, and lab automation. The offset is that customer funding cycles and government policy can delay orders.
At $510.00, the market is paying for a recovery in organic growth and high-single-digit EPS compounding. Margin of safety improves if the stock holds near the base-case range while free cash flow and leverage improve.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TMO quote reference | $510.00 intraday reference on July 8, 2026 | StockAnalysis TMO overview | July 8, 2026 |
| Market capitalization verification | $189.53 billion reported and $189.53 billion calculated from $510.00 x 371.62 million shares | Pineify financial_rigor.py and StockAnalysis TMO market cap | July 8, 2026 |
| Shares outstanding | 371.62 million shares outstanding | StockAnalysis TMO statistics | July 8, 2026 |
| FY2025 revenue | $44.56 billion, up 4% from FY2024 | Thermo Fisher FY2025 results release | July 8, 2026 |
| FY2025 adjusted EPS | $22.87, up 5% from FY2024 | Thermo Fisher FY2025 results release | July 8, 2026 |
| Q1 2026 revenue and adjusted EPS | $11.01 billion revenue and $5.44 adjusted EPS | Thermo Fisher Q1 2026 reconciliation package | July 8, 2026 |
| Cash and short-term investments | $10.105 billion at December 31, 2025 | Thermo Fisher FY2025 balance sheet | July 8, 2026 |
| Total debt | $39.385 billion at December 31, 2025 before Q1 2026 balance-sheet changes | Thermo Fisher FY2025 balance sheet | July 8, 2026 |
| TTM revenue and EPS | $45.20 billion revenue and $18.19 EPS | StockAnalysis TMO statistics | July 8, 2026 |
| Technical references | 50-day MA $474.47, 200-day MA $526.87, RSI 62.80, 20-day average volume 2.19 million | StockAnalysis TMO statistics | July 8, 2026 |
| 52-week range | $403.36 to $643.99 | MarketWatch TMO quote | July 8, 2026 |
| Management continuity | Marc Casper has been CEO since October 2009 and chairman since February 2020 | Thermo Fisher leadership page | July 8, 2026 |
| Governance and ownership controls | 2026 proxy describes stock ownership requirements and a CEO post-vest stock holding requirement | Thermo Fisher 2026 proxy statement | July 8, 2026 |
This TMO AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public data as of July 8, 2026 and can be wrong if earnings, guidance, rates, end-market demand, acquisitions, regulations, or market sentiment change.
